Texas Oncology is closed in observance of the coming holiday. View More Important Notifications x
texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials



John Sandbach, M.D.

John Sandbach, M.D.

Provider Type: Physician


Board Certifications

  • Hematology
  • Internal Medicine
  • Medical Oncology

General Summary

John F. Sandbach M.D. specializes in medical oncology and hematology. He has had additional training in cancer genetics.


  • Undergraduate
    University of Kentucky, Lexington, KY
  • Medical School
    University of Kentucky Medical School, Lexington, KY
  • Internal Medicine
    University of North Carolina, Chapel Hill, NC
  • Hematology and Medical Oncology fellowship
    University of North Carolina , Chapel Hill, NC
  • City of Hope Advanced Cancer Genetics Risk Program, 2010

Research Interest

Medical Practice

  • Austin Diagnostic Clinic, 1977 – 1994
  • Texas Oncology, 1994 – present
  • Consultant, Handbook of Nonprescription Drugs, Fifth Edition
  • American Pharmaceutical Association, 1977 Consultant, Scientific Publications Committee of Texas Medicine, published by the Texas Medical Association, 1980 – 1996
  • Consultant, Archives of Internal Medicine, Editorial Review Board, 1985 – 1994
  • Editorial Board, Investigational New Drugs, 1986 – 1996
  • American Society of Clinical Oncology Chemotherapy Sensitivity and Resistance Assay Working Group, 2003
  • Southwestern Oncology Group Breast Committee, 1983 – 1990
  • US Oncology Medical Oncology Research Chair
  • 2001 – 2012 Texas Oncology Board of Directors, 1998 – 2002
  • Texas Oncology Executive Committee, 2002 – present
  • Regional Director Texas Oncology Austin/Waco, 2002 – present
  • Texas Oncology / US Oncology Joint Operating Committee, 2002 – present
  • Managing Partner Texas Oncology Austin, 1994 – present
  • Director Texas Oncology Genetics Risk Evaluation and Testing Program
  • Co-Director US Oncology Genetics Risk Evaluation and Testing Program
  • USON National Policy Board 2010 to present

Other Information

Dr. Sandbach has been happily married to Gene Anne since they met while he was in medical school and she was in Pharmacy School. They have three children. Emily practices internal medicine in Colorado Springs in a clinic that addresses the medical needs of the underserved patient population. Anna studying to be a psychologist and is enrolled at St Edwards University. John lives in Maui. He is a chef and owns a Texas style barbeque business, Smoke and Spice Maui. The two grandchildren (John Kaden and Haylee Mae) were born in Maui. Doctor Sandbach, when not visiting the grandchildren, likes to fly fish and travel with his Gene Anne.

Dr. Sandbach has authored and co-authored over 20 peer reviewed scientific papers and presentations. He has been the Principal Investigator or a co-investigator on numerous research studies. His most recent research has been in the field of cancer genetics.

Accolades & Memberships

  • American Society of Clinical Oncology
  • American Medical Association
  • Travis County Medical Society
  • Roche Medical Scholarship 1970-1971
  • Alpha Omega Alpha Honorary Society 1971
  • Outstanding Intern – University of North Carolina College of Medicine 1972
  • Health Care Hero – Austin Business Journal – 2006
  • Outstanding Alumni University of Kentucky College of Medicine 2009
  • Austin Community Foundation – Jordan Award  for Outstanding Community Service – 2010
  • Hospice Austin Notable Doner

Community Service

  • Hospice Austin – Founder 1984
  • Hospice Austin - Chairman of the Board 1979-1984
  • United Action for the Elderly  1986 -1988
  • Board of Directors, 1986 – 1987 Board of Directors, Hospice Austin,  1979 – 1984, 1993 – 1998
  • Physician Advisory Committee, Hospice Austin 2000 to 2010
  • The Austin Diagnostic Clinic Research Foundation
  • Board of Directors, 1986 – 1990
  • Vice Chairman, 1989 – 1990
  • American Society of Clinical Oncology Education Committee, 1983 – 1984
  • American Society of Clinical Oncology Scientific Program Committee, 1984 – 1985
  • American Society of Clinical Oncology Nominations Committee, 1986
  • Hospice Austin Foundation, 2006-2010


  • A Study of Triple-Negative Breast Cancer Patients Tested With a 25-Gene Panel of Hereditary Cancer Genes.

    2015 ASCO Annual Meeting, 2015

  • Experience in the Community Oncology Practice with a 25-Gene Hereditary Cancer Panel

    San Antonio Breast Cancer Symposium, 2014

  • ER as a Predictor of Early Breast Cancer (EBC) Outcomes in Patients ≤ 40 Years.

    2013 ASCO Annual Meeting, 2013

  • Prevalence of BRCA Mutations in an Unselected Population of Triple-Negative Breast Cancer

    Hartman, 2012

  • A Structured Genetic Risk Evaluation and Testing Program in the Community Oncology Practice Increases Identification of Individuals at Risk for BRCA Mutations

    Compass Oncology, 2012

Show all Publications
  • Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.

    Myriad Genetic Laboratories, Inc., 2012

  • Hereditary Breast and Ovarian Cancer Testing Integration and Outcomes within Community Oncology Practices.

    Community Oncology, 2010

  • Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer.

    Journal of Clinical Oncology, 2010

  • A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer

    ASC Journal of Clinical Oncology, 2007

  • A Phase II study of gemcitabine plus zoledronic acid in Stage IV cancer of the pancreas.

    ASCO Gastrointestinal Cancers Symposium, 2006

  • Are granulocyte colony-stimulating growth factors (CSF’s) needed to prevent febrile neutropenia (FN) for course #1 of adjuvant chemotherapy with “standard” doxorubicin-cyclophosphamide (ASC) Results from two consecutive US Oncology community adjuvant trials.

    Breast Cancer Research and Treatment, 2006

  • Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. 

    Journal of Clinical Oncology, 2006

  • A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer.

    Breast Cancer Research and Treatment, 2004